StockData
Galectin Therapeutics Inc logo

Galectin Therapeutics Inc (GALT) stock

GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.91−0.11 (-3.64%)

Close on Nov 17, 2026Market cap $293.47MP/E –Yield –

Galectin Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Galectin Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $8.91M, down 68.7% year over year. For fiscal 2025 it was $14.29M, down 60.9% from the year before. Over ten years it grew 0.9% a year on average. The highest annual figure on record is $36.57M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$14.29M-60.9%
FY2024Dec 31, 2024$36.57M+13.8%
FY2023Dec 31, 2023$32.13M+1.2%
FY2022Dec 31, 2022$31.74M+33.2%
FY2021Dec 31, 2021$23.82M+32.5%
FY2020Dec 31, 2020$17.98M+140.7%
FY2019Dec 31, 2019$7.47M+15.4%
FY2018Dec 31, 2018$6.47M-44.8%
FY2017Dec 31, 2017$11.72M-23.5%
FY2016Dec 31, 2016$15.33M+16.9%
FY2015Dec 31, 2015$13.11M+55.7%
FY2014Dec 31, 2014$8.43M+48.1%
FY2013Dec 31, 2013$5.69M+25.6%
FY2012Dec 31, 2012$4.53M+27.4%
FY2011Dec 31, 2011$3.55M+233.2%
FY2010Dec 31, 2010$1.07M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.14M-34.5%
Q1 FY2026Mar 31, 2026$2.23M-65.6%
Q4 FY2025Dec 31, 2025$1.93M-82.6%
Q3 FY2025Sep 30, 2025$2.61M-65.6%
Q2 FY2025Jun 30, 2025$3.26M-66.8%
Q1 FY2025Mar 31, 2025$6.49M-19.5%
Q4 FY2024Dec 31, 2024$11.11M+35.0%
Q3 FY2024Sep 30, 2024$7.60M-1.8%
Q2 FY2024Jun 30, 2024$9.81M+33.1%
Q1 FY2024Mar 31, 2024$8.05M-8.5%
Q4 FY2023Dec 31, 2023$8.23M-8.6%
Q3 FY2023Sep 30, 2023$7.73M+17.2%
Q2 FY2023Jun 30, 2023$7.37M-8.7%
Q1 FY2023Mar 31, 2023$8.80M+9.2%
Q4 FY2022Dec 31, 2022$9.01M+53.8%
Q3 FY2022Sep 30, 2022$6.60M-0.2%
Q2 FY2022Jun 30, 2022$8.07M+25.2%
Q1 FY2022Mar 31, 2022$8.06M+64.5%
Q4 FY2021Dec 31, 2021$5.86M-8.1%
Q3 FY2021Sep 30, 2021$6.61M+38.3%
Q2 FY2021Jun 30, 2021$6.45M+37.8%
Q1 FY2021Mar 31, 2021$4.90M+128.5%
Q4 FY2020Dec 31, 2020$6.37M+67.8%
Q3 FY2020Sep 30, 2020$4.78M+218.0%
Q2 FY2020Jun 30, 2020$4.68M+207.6%
Q1 FY2020Mar 31, 2020$2.14M+231.9%
Q4 FY2019Dec 31, 2019$3.80M+218.5%
Q3 FY2019Sep 30, 2019$1.50M-0.1%
Q2 FY2019Jun 30, 2019$1.52M+3.1%
Q1 FY2019Mar 31, 2019$646.00K-71.9%
Q4 FY2018Dec 31, 2018$1.19M+19.0%
Q3 FY2018Sep 30, 2018$1.51M-57.0%
Q2 FY2018Jun 30, 2018$1.48M-57.1%
Q1 FY2018Mar 31, 2018$2.30M-39.1%
Q4 FY2017Dec 31, 2017$1.00M-70.8%
Q3 FY2017Sep 30, 2017$3.50M+6.5%
Q2 FY2017Jun 30, 2017$3.44M–
Q1 FY2017Mar 31, 2017$3.77M–
Q4 FY2016Dec 31, 2016$3.43M–
Q3 FY2016Sep 30, 2016$3.29M–

More Galectin Therapeutics figures

See a number that looks wrong?